Under the new name Cencora, the company unifies its 46,000 employees – across several global business segments – under one identity.
Latest In Pharmaceutical & Health Care
The New York-based health care products distributor made acquisitions in Australia and Brazil.
The acquisition is expected to close in 2023's third quarter.
Our long-awaited annual rundown of the top distributors across 17 industrial, construction and commercial products sectors is available to view and download.
It could take until the end of 2023 to complete, after which 3M will retain a 19.9% stake.
MDM’s new report, Markets Forecast, offers quarterly revenue projections for the wholesale distribution industry, plus breakouts for select categories, for the current calendar quarter and the next fiscal year. The inaugural Forecast looks at post-pandemic projections for distributors as a whole, plus specific sectors.
MDM’s quarterly survey in partnership with investment banking firm Baird reveals that distributor revenues decelerated sharply in 2Q but not as bad as feared at the beginning of the pandemic shutdown. One consensus among more than 550 participants: Distributors began rethinking the way they manage talent.
For the first nine months, sales were $133.9 billion, up 7.5% year-over-year.
Profit for the quarter was $477 million compared to a loss of $80 million in 2019.
The company reported a loss for the quarter of $14.1 million.
Brian Tyler succeeds John Hammergren in the role.
The acquisition would expand the lab-equipment companys presence in the field of gene therapy.
Healthcare distributor appoints Edward A. Pesicka to top post, effective March 4.
Fiscal second-quarter increase led by growth in the companys pharmaceuticals segment.
Distributor reports solid sales growth in the U.S., double-digit increase in medical-surgical solutions business.
Industrial sales fell 0.3 percent in the fourth quarter.
Company hires Brian Rice as executive vice president, chief information officer and customer support services.
Distributor will move its headquarters from San Francisco to Las Colinas, Texas, effective April 1.
Fiscal first-quarter sales reach $35.2 billion, driven by growth in both pharmaceutical and medical segments.
